Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time—using genomic data to individualize treatment protocol
…, JM Skierka, MJ Ferber, JL Black, LM Baudhuin… - Mayo Clinic …, 2014 - Elsevier
Objective To report the design and implementation of the Right Drug, Right Dose, Right
Time—Using Genomic Data to Individualize Treatment protocol that was developed to test the …
Time—Using Genomic Data to Individualize Treatment protocol that was developed to test the …
MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps
L Wang, LM Baudhuin, LA Boardman, KJ Steenblock… - Gastroenterology, 2004 - Elsevier
Background & Aims : MYH-associated polyposis is a recently described disease that is
characterized by multiple colorectal adenomas and a recessive pattern of inheritance. Individuals …
characterized by multiple colorectal adenomas and a recessive pattern of inheritance. Individuals …
Sphingosylphosphorylcholine and lysophosphatidylcholine are ligands for the G protein-coupled receptor GPR4
K Zhu, LM Baudhuin, G Hong, FS Williams… - Journal of Biological …, 2001 - ASBMB
Sphingosylphosphorylcholine (SPC) and lysophosphatidylcholine (LPC) are bioactive lipid
molecules involved in numerous biological processes. We have recently identified ovarian …
molecules involved in numerous biological processes. We have recently identified ovarian …
[HTML][HTML] Preemptive pharmacogenomic testing for precision medicine: a comprehensive analysis of five actionable pharmacogenomic genes using next-generation …
…, SA Lagerstedt, LJ Train, LM Baudhuin… - The Journal of Molecular …, 2016 - Elsevier
Significant barriers, such as lack of professional guidelines, specialized training for interpretation
of pharmacogenomics (PGx) data, and insufficient evidence to support clinical utility, …
of pharmacogenomics (PGx) data, and insufficient evidence to support clinical utility, …
Clopidogrel pharmacogenetics: state-of-the-art review and the TAILOR-PCI Study
…, RM Weinshilboum, L Wang, LM Baudhuin… - Circulation …, 2019 - Am Heart Assoc
Common genetic variation in CYP2C19 (cytochrome P450, family 2, subfamily C, polypeptide
19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-…
19) *2 and *3 alleles leads to a loss of functional protein, and carriers of these loss-of-…
Plasma ceramides: a novel predictor of major adverse cardiovascular events after coronary angiography
…, LJ Donato, SC Bryant, LM Baudhuin… - … , and vascular biology, 2018 - Am Heart Assoc
Objective— Ceramides are sphingolipids involved with cellular signaling. Synthesis of
ceramides occurs in all tissues. Ceramides accumulate within tissues and the blood plasma …
ceramides occurs in all tissues. Ceramides accumulate within tissues and the blood plasma …
[HTML][HTML] Confirming variants in next-generation sequencing panel testing by Sanger sequencing
Current clinical laboratory practice guidelines for next-generation sequencing (NGS) do not
provide definitive guidance on confirming NGS variants. Sanger confirmation of NGS results …
provide definitive guidance on confirming NGS variants. Sanger confirmation of NGS results …
Warfarin sensitivity genotyping: a review of the literature and summary of patient experience
TP Moyer, DJ O'Kane, LM Baudhuin, CL Wiley… - Mayo Clinic …, 2009 - Elsevier
The antithrombotic benefits of warfarin are countered by a narrow therapeutic index that
contributes to excessive bleeding or cerebrovascular clotting and stroke in some patients. This …
contributes to excessive bleeding or cerebrovascular clotting and stroke in some patients. This …
Sphingosylphosphorylcholine is a ligand for ovarian cancer G-protein-coupled receptor 1
Y Xu, K Zhu, G Hong, W Wu, LM Baudhuin, Y Xiao… - Nature cell …, 2000 - nature.com
Sphingosylphosphorylcholine (SPC) is a bioactive lipid that acts as an intracellular and
extracellular signalling molecule in numerous biological processes. Many of the cellular actions …
extracellular signalling molecule in numerous biological processes. Many of the cellular actions …
Outcome of whole exome sequencing for diagnostic odyssey cases of an individualized medicine clinic: the Mayo Clinic experience
…, MJ Ferber, ED Wieben, G Farrugia, LM Baudhuin… - Mayo Clinic …, 2016 - Elsevier
Objective To describe the experience and outcome of performing whole-exome sequencing
(WES) for resolution of patients on a diagnostic odyssey in the first 18 months of an …
(WES) for resolution of patients on a diagnostic odyssey in the first 18 months of an …
